The subject of this publication is the conclusion of discount agreements for the following X-ray contrast media (ATC code according to WHO: V08):

- lot 1 amidotrizoic acid,

- lot 2 ioxitalamic acid,

- lot 3 iohexol,

- lot 4 iopamidol,

- lot 5 iopromide,

- lot 6 Ioversol,

- lot 7 iodixanol,

- Lot 8 Iomeprol up to 350 mg,

- Lot 9 Iomeprol 400 mg,

- lot 10 iobitridol,

- lot 11 ethyl esters of iodinated fatty acids,

Lot 12 barium sulfate with suspending agent,

- lot 13 gadopentetic acid,

- lot 14 gadoteric acid,

- lot 15 gadoteridol,

- lot 16 gadobenic acid,

- Lot 17 Gadobutrol,

- lot 18 human albumin microspheres,

- lot 19 gadoxetic acid,

- lot 20 phospholipid microspheres,

- Lot 21 sulfur hexafluoride.

For further information see point II.2.4) of the announcement.

The subject of this lot is the conclusion of discount agreements for the active ingredient amidotrizoic acid (ATC according to WHO: V08AA01) as part of a so-called "open-house model". Deviating from the beginning of the contract period, the discount is granted at the earliest from 1.4.2020. The contract is concluded as part of the open house process. The AOK PLUS does not guarantee individual contract partners exclusivity. The purchase quantity is unknown when the agreement is concluded and is particularly dependent on the demand of the insured, the development of the number of insured, the prescription behavior of the contract doctors and the dispensing and stockpiling behavior of the public pharmacies. The client does not guarantee minimum purchase quantities.

Interested contractors can conclude discount agreements during the period from 13.3.2020 to 31.3.2021. The discount agreements and the “open house procedure” end at the latest on March 31, 2021, regardless of the date of conclusion of the contract. Irrespective of this, discount agreements and the “open house procedure” will be terminated before March 31, 2021, as a result of a formal award procedure in accordance with the regulations of Part 4 of the GWB with one or more contractual partners, exclusive agreements to those under II.1.1) mentioned active substances come into force.

According to the experience of AOK PLUS, exclusive discount agreements generally come into force 8 to 12 months after the publication of the relevant announcement in the TED supplement to the Official Journal of the European Union. The future contracting parties are asked to inform themselves regularly about these announcements in the TED supplement to the Official Journal of the European Union. Interested contractors can request the participation documents as well as the discount agreement from the contact point mentioned under I.1) by specifying the lot and active substance by email. A precondition for the conclusion of a discount agreement is that the interested contractor completes, signs, dates and submits all the participation documents (self-declaration for non-existence of reasons for exclusion, discount agreement in duplicate, declaration of conformity) on time. A discount agreement is concluded with each contractor who meets the participation requirements. The participation documents must be submitted in full by post to the contact point mentioned under I.1), for the first time by March 12, 2020 and then by the 15th of each month (deadline for receipt). Access depends on the contact point mentioned under I.1). If the 15th of a month falls on a Saturday, Sunday or national holiday, the next working day will take the place of such a day. If received later (after March 12, 2020 or the 15th of a month), the submitted participation documents will be taken into account on the 15th of the following month.

The discount agreement will come into effect on March 1st, 2020 if both parties sign the contract up to and including March 31st, 2020. The signing takes place until the end of the month in which the participation documents must have been received by AOK PLUS.

The AOK health partner portal (www.aok-gesundheitpartner.de) is used to publish the discounted contrast media. AOK PLUS ensures publication by the first day of the month after the discount agreement has been signed by AOK PLUS. The first publication will take place on 1.4.2020.

If anything is unclear and you have any questions about the discount agreement, please only send an email to the contact point listed under I.1). AOK PLUS reserves the right to make such questions and the answers to them available anonymously to all other interested contractors, provided that they are of general interest in the course of the procedure.

The subject of this lot is the conclusion of discount agreements for the active ingredient iobitridol (ATC according to WHO: V08AB11) as part of a so-called "open-house model".

For more information, see lot 1 on the active substance amidotrizoic acid, point II.2.4) of the notice.

The subject of this lot is the conclusion of discount agreements for the active ingredient ethyl ester of iodinated fatty acids (ATC according to WHO: V08AD01) as part of a so-called "open-house model".

For more information, see lot 1 on the active substance amidotrizoic acid, point II.2.4) of the notice.

The subject of this lot is the conclusion of discount agreements for the active ingredient barium sulfate with suspending agent (ATC according to WHO: V08BA01) as part of a so-called "open-house model".

For more information, see lot 1 on the active substance amidotrizoic acid, point II.2.4) of the notice.

The subject of this lot is the conclusion of discount agreements for the active ingredient gadopentetic acid (ATC according to WHO: V08CA01) as part of a so-called "open-house model".

For more information, see lot 1 on the active substance amidotrizoic acid, point II.2.4) of the notice.

The subject of this lot is the conclusion of discount agreements for the active ingredient gadoteric acid (ATC according to WHO: V08CA02) as part of a so-called "open-house model".

For more information, see lot 1 on the active substance amidotrizoic acid, point II.2.4) of the notice.

The subject of this lot is the conclusion of discount agreements for the active ingredient gadoteridol (ATC according to WHO: V08CA04) as part of a so-called "open-house model".

For more information, see lot 1 on the active substance amidotrizoic acid, point II.2.4) of the notice.

The subject of this lot is the conclusion of discount agreements for the active ingredient gadobenic acid (ATC according to WHO: V08CA08) as part of a so-called “open house model”.

For more information, see lot 1 on the active substance amidotrizoic acid, point II.2.4) of the notice.

The subject of this lot is the conclusion of discount agreements for the active ingredient gadobutrol (ATC according to WHO: V08CA09) as part of a so-called "open-house model".

For more information, see lot 1 on the active substance amidotrizoic acid, point II.2.4) of the notice.

The subject of this lot is the conclusion of discount agreements for the active ingredient gadoxetic acid (ATC according to WHO: V08CA10) as part of a so-called "open-house model".

For more information, see lot 1 on the active substance amidotrizoic acid, point II.2.4) of the notice.

The subject of this lot is the conclusion of discount agreements for the active ingredient human albumin microspheres (ATC according to WHO: V08DA01) as part of a so-called "open-house model".

For more information, see lot 1 on the active substance amidotrizoic acid, point II.2.4) of the notice.

The subject of this lot is the conclusion of discount agreements for the active substance ioxitalamic acid (ATC according to WHO: V08AA05) within the framework of a so-called “open house model”.

For more information, see lot 1 on the active substance amidotrizoic acid, point II.2.4) of the notice.

The subject of this lot is the conclusion of discount agreements for the active ingredient phospholipid microspheres (ATC according to WHO: V08DA04) as part of a so-called "open-house model".

For more information, see lot 1 on the active substance amidotrizoic acid, point II.2.4) of the notice.

The subject of this lot is the conclusion of discount agreements for the active ingredient sulfur hexafluoride (ATC according to WHO: V08DA05) as part of a so-called "open-house model".

For more information, see lot 1 on the active substance amidotrizoic acid, point II.2.4) of the notice.

The subject of this lot is the conclusion of discount agreements for the active substance iohexol (ATC according to WHO: V08AB02) as part of a so-called "open-house model".

For more information, see lot 1 on the active substance amidotrizoic acid, point II.2.4) of the notice.

The subject of this lot is the conclusion of discount agreements for the active ingredient iopamidol (ATC according to WHO: V08AB04) within the framework of a so-called "open-house model".

For more information, see lot 1 on the active substance amidotrizoic acid, point II.2.4) of the notice.

The subject of this lot is the conclusion of discount agreements for the active ingredient iopromide (ATC according to WHO: V08AB05) as part of a so-called "open-house model".

For more information, see lot 1 on the active substance amidotrizoic acid, point II.2.4) of the notice.

The subject of this lot is the conclusion of discount agreements for the active ingredient Ioversol (ATC according to WHO: V08AB07) as part of a so-called "open-house model".

For more information, see lot 1 on the active substance amidotrizoic acid, point II.2.4) of the notice.

The subject of this lot is the conclusion of discount agreements for the active ingredient iodixanol (ATC according to WHO: V08AB09) as part of a so-called "open-house model".

For more information, see lot 1 on the active substance amidotrizoic acid, point II.2.4) of the notice.

The subject of this lot is the conclusion of discount agreements for the active ingredient Iomeprol (ATC according to WHO: V08AB10) up to 350 mg as part of a so-called "open-house model".

For more information, see lot 1 on the active substance amidotrizoic acid, point II.2.4) of the notice.

The subject of this lot is the conclusion of discount agreements for the active ingredient Iomeprol (ATC according to WHO: V08AB10) 400 mg as part of a so-called "open-house model".

For more information, see lot 1 on the active substance amidotrizoic acid, point II.2.4) of the notice.